ifosfamide / Generic mfg. - LARVOL DELTA

Unusual Ampullary Presentation of Pediatric Burkitt Lymphoma: Case Report and Literature Review. (PubMed, Clin Med Insights Case Rep) - "Given persistent cholestasis and bleeding risk, the patient underwent Roux-en-Y choledochojejunostomy for biliary decompression, followed by initiation of rituximab-cyclophosphamide-vincristine-doxorubicin-high-dose methotrexate/rituximab-ifosfamide-etoposide-high-dose cytarabine (R-CODOX-M/R-IVAC) with central nervous system prophylaxis...Ampullary BL should be considered in pediatric patients with obstructive jaundice and upper gastrointestinal bleeding. Surgical biliary decompression can stabilize cholestasis and facilitate timely multi-agent chemotherapy."

Journal • B Cell Non-Hodgkin Lymphoma • Burkitt Lymphoma • Cholestasis • Constipation • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Hepatology • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pain • Pediatrics • CD20 • MME • MYC

Rechallenge of immunotherapy after rituximab-induced Takotsubo syndrome: a case report and review of the literature. (PubMed, Eur Heart J Case Rep) - "Although caution is recommended in patients with underlying cardiovascular disease, its cardiotoxic potential-particularly in relation to Takotsubo syndrome (TS)-remains underrecognized compared to other agents such as trastuzumab...Due to disease progression, the chemotherapy regimen was later changed to etoposide and ifosfamide...When rechallenge is considered, individualized risk assessment and cardioprotective strategies are essential. This case also illustrates the importance of differentiating TS from other cardiotoxicities, such as anthracycline-induced cardiomyopathy, particularly in cancer patients with multiple cardiovascular risk factors."

IO biomarker • Journal • B Cell Lymphoma • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Diffuse Large B Cell Lymphoma • Heart Failure • Hematological Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Extranodal (Nasal Variant) NK/T -Cell Lymphoma of Head and Neck: Our Experience From a Tertiary Care Centre. (PubMed, Asia Pac J Clin Oncol) - "This is the first detailed ENNK cohort from Northeast India; patients referred to our center as refractory chronic sinusitis or granulomatous disease turned out to be ENNK. Practicing otorhinolaryngologists in Asia should include ENNK in differential diagnoses for early detection and improved outcomes."

Journal • Epstein-Barr Virus Infections • Hematological Malignancies • Lymphoma • Natural Killer/T-cell Lymphoma • Oncology • Otorhinolaryngology • Respiratory Diseases • Sinusitis • T Cell Non-Hodgkin Lymphoma • NCAM1

Conventional cytotoxic chemotherapy-associated nephrotoxicity. (PubMed, Kidney Int) - "While numerous conventional cytotoxic chemotherapy drugs are nephrotoxic, some of the most common offenders that clinicians encounter are cisplatin, ifosfamide, methotrexate, pemetrexed, gemcitabine, melphalan, and mitomycin C. They will be the focus of this review. This ADQI Consensus Conference Workgroup covered cytotoxic chemotherapy nephrotoxicity and reviewed several aspects of their adverse renal complications. Included are 1) epidemiology of each agent's nephrotoxicity, 2) mechanisms of nephrotoxicity, 3) predisposing risk factors, 4) clinical manifestations of nephrotoxicity, 5) prevention and management of kidney injury, and 6) research agenda addressing knowledge gaps for the noted nephrotoxic cytotoxic chemotherapy."

Journal • Acute Kidney Injury • Chronic Kidney Disease • Nephrology • Oncology • Renal Disease

Congenital mesoblastic nephroma: a single-center retrospective study. (PubMed, Transl Pediatr) - "Two relapsed patients received salvage chemotherapy [vincristine-actinomycin D-cyclophosphamide (VAC) or ifosfamide-carboplatin-etoposide (ICE)], which showed limited efficacy. One relapsed patient with TPM3::NTRK1 received larotrectinib but died two months later; another with EGFR-KDD experienced disease stabilization after afatinib plus programmed cell death protein 1 (PD-1) blockade following progression on entrectinib and anlotinib...While most patients experienced favorable outcomes following surgery, relapsed cases highlight the challenges associated with molecularly atypical disease. These observations are descriptive in nature and underscore the need for larger collaborative studies to better define prognostic factors and optimal management strategies in CMN."

IO biomarker • Journal • Retrospective data • Kidney Cancer • Oncology • Pediatrics • Renal Cell Carcinoma • Solid Tumor • EGFR • ETV6 • NTRK1 • NTRK3 • TPM3

Dual-Biosensor for Five Drugs Detection in Precision Oncology. (PubMed, Bionanoscience) - "In this work, we propose a novel dual-biosensor platform for TDM, designed to simultaneously detect multiple chemotherapeutic agents-cyclophosphamide, ifosfamide, etoposide, methotrexate, and 5-fluorouracil-for precision oncology. By integrating MWCNTs with cytochrome P450 enzymes (CYP3A4 and CYP2B6), our platform achieves enhanced electron transfer and substrate specificity, enabling sensitive and selective detection of the five chemotherapeutic drugs, individually and in combination, within clinically relevant ranges. Designed for portability and rapid analysis, this dual-biosensor platform enables real-time, cost-effective drug monitoring at the point-of-care, advancing personalized cancer treatment with greater precision and accessibility."

Journal • Oncology • CYP3A4

Sublethal DNA damage switches off B cell effector programs in an RA-FLS-PBMC co-culture. (PubMed, Cell Death Discov) - "Peripheral blood mononuclear cells from healthy donors were co-cultured with RA fibroblast-like synoviocytes and exposed once to an IC₂₀ or IC₅₀ dose/concentration of γ-irradiation (γ-IR), hydrogen peroxide (H₂O₂), or the oxazaphosphorine metabolite 4-hydroperoxyifosfamide (4-OOH IFA)...At 2 Gy, overall cell viability remained above 80%, whereas IL-10 expression declined by approximately 70%, indicating functional silencing in the absence of substantial cytotoxicity. Conceptually, targeting this vulnerability might help to dampen B cell activity in RA while largely preserving overall immune viability and T cell competence."

Journal • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • IL10

Axial Round Cell Sarcoma Harboring a Non-ETS EWSR1 Rearrangement: Diagnostic Challenges and Clinical Implications. (PubMed, Cureus) - "Surgical resection and cervicothoracic fixation were performed, followed by radiotherapy (30 Gy/10 fractions) and Ewing-based chemotherapy (doxorubicin/ifosfamide). Local recurrence occurred despite multimodal therapy. This case highlights the clinical and diagnostic challenges associated with EWSR1-rearranged non-ETS sarcomas, which exhibit distinct molecular behaviors, morphology, and treatment responses compared to classical Ewing sarcoma."

Journal • Ewing Sarcoma • Musculoskeletal Pain • Oncology • Pain • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • CCND1 • CD99 • EWSR1 • FLI1 • SOX10

Solitary intracranial dural-based Ewing's sarcoma in a pregnant female: A case report. (PubMed, Radiol Case Rep) - "After the operation, the patient was treated with vincristine-doxorubicin-cyclophosphamide and ifosfamide-etoposide chemotherapy, which resulted in a partial radiological response. This case illustrates the diagnostic difficulties associated with intracranial ES due to its radiological similarity to meningioma and stresses the importance of immunohistochemical and genetic analysis for a conclusive diagnosis. Early multimodal management is vital for improving survival in such rare cases."

Journal • Brain Cancer • Ewing Sarcoma • Meningioma • Oncology • Pain • Sarcoma • Solid Tumor • CD99 • EWSR1

Primary cardiac angiosarcoma with isolated superior vena cava syndrome: a case report. (PubMed, J Med Case Rep) - "Patients with cardiac angiosarcoma may present with atypical or nonspecific symptoms, such as with our patient presenting with isolated superior vena cava syndrome, and an atypical presentation may further delay the diagnosis. Late presenting cardiac angiosarcoma contributes to a worse prognosis and higher likelihood of metastasis at the time of diagnosis. Treatment typically includes chemotherapy and radiation but surgical excision, alone or in combination with other therapies, can provide the best prognosis. Early detection of cardiac angiosarcoma is crucial for improving outcomes."

Journal • Angiosarcoma • Cardiovascular • Congestive Heart Failure • Heart Failure • Oncology • Pain • Pulmonary Disease • Sarcoma • Solid Tumor

5-fluoro-deoxyglucose PET/CT response after neoadjuvant chemotherapy predicts long-term outcomes in soft tissue sarcomas: Results from a prospective trial. (PubMed, Cancer) - "An SUVmax reduction verified on FDG-PET/CT imaging after neoadjuvant chemotherapy was a strong predictor of long-term outcomes. Metabolic imaging at treatment completion identified responders, supporting continued therapy in initially nonresponsive patients and guiding personalized treatment strategies."

Journal • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

The European Union's medicines regulator said on Tuesday it expects Baxter International's (BAX.N), opens new tab cancer ​drugs containing ifosfamide will remain in shortage in the bloc ‌well into the first quarter of next year. (Reuters) - "The European Medicines Agency said ​the shortage was due to a technical disruption at ⁠Baxter's contract manufacturing site, but did not disclose details....The reduced ​capacity at the site is resulting in limited supply of ifosfamide which will ‌gradually ⁠improve through 2026, Baxter said in an emailed response to Reuters."

Commercial • Cervical Cancer • Small Cell Lung Cancer • Testicular Cancer

FIRST DISCLOSURE OF EPCORITAMAB + R-ICE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL) ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT): EPCORE NHL-2 (EHA 2025) - P1/2 | "Background: Approximately 50% of patients (pts) with LBCL are refractory to salvage chemoimmunotherapy (CIT), like rituximab, ifosfamide, carboplatin, and etoposide (R-ICE)...Epcoritamab (epcor), a subcutaneous CD3xCD20 bispecific antibody, has previously demonstrated high CR rates when combined with the salvage CIT rituximab, dexamethasone, cytarabine, and oxaliplatin or carboplatin (R-DHAX/C)... Epcor + R-ICE demonstrated high CR rates in pts with R/R DLBCL eligible for ASCT, most of whom were high risk, having progressed <12 mo of 1L tx. Safety was manageable, with no discontinuations due to AEs. These results continue to demonstrate that epcor, when combined with CIT, may optimize salvage tx, increasing the proportion of pts proceeding to ASCT compared with historical rates, providing a greater chance of a cure."

Clinical • Anemia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Thrombocytopenia • Transplantation

Case Report of Decreased Cholinesterase Levels During Treatment with Prifosfamide Mesylate in a Patient with Chronic HBV Infection (APASL 2026) - No abstract available

Case report • Clinical • Hepatitis B • Infectious Disease

Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL) (clinicaltrials.gov) - P3 | N=200 | Recruiting | Sponsor: Children's Cancer Group, China | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial primary completion date • Hematological Malignancies • Lymphoma • Oncology

Primary urethral squamous cell carcinoma: Insights and outcomes from a 27-year institutional experience. (ASCO-GU 2026) - "Among the 35 patients, 16 (45.7%) received neoadjuvant chemotherapy, with gemcitabine-based regimens being the most common (N=8), followed by TIP (paclitaxel, ifosfamide, and cisplatin) in 6 patients...Seventeen (48.6%) patients received adjuvant chemotherapy or immunotherapy, most commonly the TIP regimen (N=5, 29.4%) and pembrolizumab (N= 4, 23.5%)... Our findings indicate that while the overall survival of primary urethral SCC patients is relatively favorable, there remains a lack of consensus regarding the standard of care for this malignancy. Additionally, despite the extended timeline of our study, the median follow-up duration was relatively short. These results highlight the need for larger multi-institutional studies with longer follow-up periods to establish a clearer standard of care for primary urethral cancer."

Clinical • Genito-urinary Cancer • Oncology • Urethral Cancer

Case Report: Complete response to the concurrent neoadjuvant radiation therapy and pembrolizumab in a locally recurrent, chemotherapy-refractory undifferentiated pleomorphic sarcoma of bone. (PubMed, Front Oncol) - "The patient initially presented with a destructive iliac mass in 2021 and underwent induction with doxorubicin/cisplatin, which was complicated by acute kidney injury and thromboembolic events, followed by hemipelvectomy...Treatment with high-dose ifosfamide provided no durable disease control, and imaging demonstrated progressive growth...Resection in June 2022 demonstrated no viable tumor, consistent with complete pathologic response. The patient has since completed one year of adjuvant pembrolizumab, with ongoing therapy and no evidence of recurrence at 24 month follow-up."

IO biomarker • Journal • Tumor mutational burden • Acute Kidney Injury • Cardiovascular • Nephrology • Oncology • Osteosarcoma • Renal Disease • Sarcoma • Solid Tumor • Undifferentiated Pleomorphic Sarcoma • SMARCA4 • TMB

LS1781: Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: Mayo Clinic | Trial completion date: Mar 2027 ➔ Nov 2033 | Trial primary completion date: Mar 2027 ➔ Feb 2031

Trial completion date • Trial primary completion date • B Cell Lymphoma • Chronic Myelomonocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • High-grade B-cell lymphoma • Hodgkin Lymphoma • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • CD4 • DNMT3A • IDH1 • IDH2 • SF3B1 • SRSF2 • TET2 • U2AF1 • ZRSR2

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma (clinicaltrials.gov) - P2 | N=45 | Recruiting | Sponsor: Memorial Sloan Kettering Cancer Center

New P2 trial • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

CyTOF analysis of targeted therapy in addition to standard of care against Ewing sarcoma tumor subpopulations (AACR 2026) - "SOC involves chemotherapy using alternating cycles of Vincristine, Doxorubicin, Cyclophosphamide (VDC) with Ifosfamide and Etoposide (IE). We have identified that the combination of romidepsin with IE, but not IE alone, leads to an increase in DNA damage in the EWS:FLI1low and cancer stem cell populations. This suggests that the addition of romidepsin to SOC may improve treatment efficacy against subpopulations of tumor cells that are known to be chemoresistant. Further, this study highlights the use of CyTOF to assess treatment effects within ES tumor subpopulations to identify therapies that may be more effective against chemoresistant populations."

Clinical • Ewing Sarcoma • Oncology • Sarcoma • Solid Tumor • EWSR1 • FLI1

BET inhibition potentiates salvage chemotherapy response through TXNIP upregulation in osteosarcoma (AACR 2026) - "In vitro combination studies showed additive-to-synergistic effects between AZD5153 and a variety of salvage agents (etoposide, SN38, and topotecan)...In vivo, dose finding studies indicated that PDX77-TT2 was resistant to salvage agents ifosfamide and SN38 but moderately sensitive to topotecan. Furthermore, AZD5153 alone or in combination with topotecan improved survival compared to single agents (p<0.05) and was well tolerated. Collectively, these data support BET inhibition alone or with salvage therapy as a promising therapeutic approach for aggressive OS, potentially mediated through TXNIP upregulation and AKT pathway suppression."

Oncology • Osteosarcoma • Sarcoma • Solid Tumor • BRD2 • BRD4 • PARP1 • PDGFRA • RPA2 • TXNIP

Development of a collection of cell lines from a genetically engineered mouse model of DICER1 syndrome-associated sarcoma for therapeutic assessment (AACR 2026) - "IVADo regimen (ifosfamide/cyclophosphamide, vincristine, actinomycin-D, doxorubicin) and CDK4/6 inhibitor were selected to treat the cells...Considering that the KRAS-mutant lung cancer cells have been reported to be hypersensitive to CDK4/6 inhibitor, we tested palbociclib sensitivity and found that only one out of two Kras-mutant cell lines was sensitive to palbociclib... We validated that HDT tumors predominantly express the Dicer1IIIb-mutant transcript and most tumors were quadriphasic (epithelial, undifferentiated blastema, stromal cells, and rhabdomyoblastic cells) with no to variable amounts of anaplastic sarcoma components. From these murine HDT tumors, we have successfully derived five HDT cell lines (HDT298, HDT340, HDT366, HDT546, and HDT1003 cell lines). Some of these cell lines have aberrant p53 expression (or p53 mutation) and Kras mutation, confirming their resemblance to human DICER1-sarcoma."

Preclinical • Lung Cancer • Oncology • Sarcoma • Solid Tumor • DICER1 • KRAS • TP53

Alveolar Soft Part Sarcoma in Pediatric and Young Adult Patients: A Report From the Children's Oncology Group Study ARST0332. (PubMed, Pediatr Blood Cancer) - "Patients with low-risk ASPS (non-metastatic, grossly resected tumors ≤ 5 cm) had excellent outcomes with surgery with or without radiation on ARST0332. Chemotherapy has been reported to be generally ineffective in ASPS and, indeed, there were no objective responses to neoadjuvant chemoradiotherapy on ARST0332. All patients treated with combination chemoradiotherapy ultimately developed disease progression/relapse. A different therapeutic approach is needed for patients with unresectable or metastatic ASPS."

Journal • Alveolar Soft Tissue Sarcoma • Oncology • Pediatrics • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Ewing sarcoma of the great toe: a rare case report. (PubMed, Int J Surg Case Rep) - "The patient received six cycles of vincristine-doxorubicin-cyclophosphamide alternating with ifosfamide-etoposide, followed by partial amputation of the distal phalanx with clear margins. Ewing sarcoma of the great toe is exceptionally rare but can be successfully treated when identified early and managed with coordinated multimodal therapy. Clinicians should maintain vigilance for malignancy in non-healing digital lesions to ensure timely intervention and durable outcomes."

Journal • Ewing Sarcoma • Oncology • Pain • Sarcoma • Solid Tumor • CD99 • EWSR1 • FLI1

ROOM TO SPARE? A PRIMARY CARDIAC ANGIOSARCOMA OCCUPIES THE RIGHT ATRIUM (ACC 2026) - "He recovered well postoperatively, received 6 cycles of doxorubicin/ifosfamide/mesna, and at 6 months has remained clinically stable without progression. Primary cardiac angiosarcoma has a median survival of less than 15 months. Early recognition of complications such as mechanical obstruction, arrhythmias and tamponade is critical, and a multimodal strategy with surgery and chemotherapy offers the best opportunity to extend survival."

Angiosarcoma • Cardiovascular • Cognitive Disorders • Heart Failure • Hepatology • Pulmonary Disease • Pulmonary Embolism • Sarcoma • Solid Tumor • Thrombosis